Ocular Hypotensive Efficacy of AR-102
Public ClinicalTrials.gov record NCT00523250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.
Study identification
- NCT ID
- NCT00523250
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Interventions
- AR-102 0.003% Ophthalmic Solution Drug
- AR-102 0.005% Ophthalmic Solution Drug
- AR-102 0.01% Ophthalmic Solution Drug
- AR-102 0.03% Ophthalmic Solution Drug
- AR-102 Vehicle Ophthalmic Solution Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2007 (Type not available)
- Primary completion
- Mar 2008 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- May 8, 2014
2007 – 2008
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Soilsh Practice | Pasadena | California | 91105 | — |
| Bacharach practice | Petaluma | California | 94954 | — |
| Hernando Eye Institute | Brooksville | Florida | 34613 | — |
| Taustine Eye Center | Louisville | Kentucky | 40217 | — |
| Mundorf Practice | Charlotte | North Carolina | 28204 | — |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | — |
| Texan Eye | Austin | Texas | 78731 | — |
| Medical Center Ophthalmology Associates | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00523250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2014 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00523250 live on ClinicalTrials.gov.